Chinese Herbal Slice Industry In Dire Straits
This article was originally published in PharmAsia News
The herbal slice industry in China, at 22.3 billion yuan or 15.5 percent of the national Traditional Chinese Medicine market in 2006, is in trouble. China's State FDA has reiterated that manufacturers without GMP authentication, or an estimated 70 percent of firms, are to shut down immediately. According to 2007 year-end statistics, only 288 out of 1,100 registered herbal slice firms have achieved GMP authentication, and 110 have undergone checks but are awaiting certification. While analysts did not expect product shortage or price hikes in the short term, the latest policy will further set back the development and internationalization of the industry, in which 60 percent of GMP authenticated firms are already barely making a profit. (Click here for more)
You may also be interested in...
Deputy CEO Nicolas Hieronimus will take L’Oreal’s helm beginning in May 2021, with Jean-Paul Agon continuing as chairman, the firm announced on 14 October. The Estee Lauder Companies hires PepsiCo’s Gibu Thomas to lead its online business, and Coty appoints its first chief digital officer.
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.